IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Santachiara et al7 reported on 87 late CP patients treated with imatinib who presented a reduction of Ig levels; these patients were treated with imatinib after IFN for CML or were affected by GIST.